Please assess the completion status of the following clinical trial:

Trial Title: A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Females only~* Consent for the collection of biopsy tissue in RNAlater solution~* Biopsy specimens that were obtained by core biopsy or incisional biopsy and placed in RNAlater solution~* Breast cancer that is:~  * unilateral~ * diagnosed histologically as invasive breast cancer without evidence of metastatic disease (except for stage IV with positive supraclavicular nodes only)~ * stage IIB, IIIA (T0-3N2), IIIB (T4N0-3 or T0-3N3), or IV (by involvement of positive supraclavicular nodes only). (Patients with clinical evidence of inflammatory breast cancer or superficial lesions must have a measurable mass in the breast or lymph nodes.)~ * measurable by physical exam, mammography, sonogram, CT scan, MRI, or x-ray~* Evidence of adequate organ function (liver, bone marrow, kidney)~* Ability to perform an adequate level of physical activity (Zubrod scale 0, 1, or 2)~* Life expectancy of at least 10 years~* Childbearing potential terminated by surgery, radiation, or menopause, or attenuated by use of an effective non-hormonal, barrier contraceptive method~* Disease-free from prior nonbreast malignancies for at least 5 years before entry~* Adequate cardiac function( measured by baseline LVEF on MUGA or echocardiogram greater than or equal to the institution's lower limit of normal)~Exclusion criteria:~* Male~* Hormonal birth control~* The use of hormonal agents or raloxifene~* Active infection~* Pregnancy or breastfeeding~* Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant~* Previous therapy for breast cancer~* Nonmalignant systemic disease that would keep the patient from being given the treatment or would prevent long-term follow-up~* Active cardiac disease that would preclude the use of epirubicin and/or Taxol~* Significant abnormal peripheral nerve disease (greater than or equal to Grade 2)~* Any prior anthracycline or taxane-containing chemotherapy~* Use of any investigational agent within one month before enrollment~* Excisional biopsy of the breast

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).